Scinai Immunotherapeutics Ltd.

NasdaqCM:SCNI Stock Report

Market Cap: US$3.0m

Scinai Immunotherapeutics Past Earnings Performance

Past criteria checks 0/6

Scinai Immunotherapeutics has been growing earnings at an average annual rate of 38%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 109.1% per year.

Key information

38.0%

Earnings growth rate

63.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate109.1%
Return on equityn/a
Net Margin-1,304.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt

Nov 10
Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt

Bionvax Pharmaceuticals GAAP EPS of -NIS0.02

Aug 25

BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan

Aug 10

We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt

Mar 31
We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt

BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering

Jan 29

Revenue & Expenses Breakdown

How Scinai Immunotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:SCNI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-435
31 Mar 240-545
31 Dec 230-655
30 Sep 230-956
30 Jun 230-856
31 Mar 230-757
31 Dec 220-656
30 Sep 220-855
30 Jun 220-875
31 Mar 220-884
31 Dec 210-883
30 Sep 210-1375
30 Jun 210678
31 Mar 210-3611
31 Dec 200-1516
30 Sep 200-10422
30 Jun 200-31323
31 Mar 200-32323
31 Dec 190-32320
30 Sep 190-32318
30 Jun 190-25215
31 Mar 190-20218
31 Dec 180-23119
30 Sep 180-15116
30 Jun 180-15215
31 Mar 180-1118
31 Dec 170-1015
30 Sep 170-712
30 Jun 170-812
31 Mar 170-512
31 Dec 160-212
30 Sep 160-312
30 Jun 160-212
31 Mar 160-312
31 Dec 150-312
30 Sep 150-212
30 Jun 150-312
31 Mar 150-211
31 Dec 140-211
30 Sep 140-212
30 Jun 140-212
31 Mar 140-212

Quality Earnings: SCNI is currently unprofitable.

Growing Profit Margin: SCNI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SCNI is unprofitable, but has reduced losses over the past 5 years at a rate of 38% per year.

Accelerating Growth: Unable to compare SCNI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SCNI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: SCNI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies